Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06723405 | Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis | PHASE2 | COMPLETED | 71 | — | — | Feb 13, 2025 | Nov 17, 2025 | Dec 4, 2025 | 12 | Australia, New Zealand |
EASI assesses the extent and severity of atopic dermatitis. EASI is a composite index with scores ranging from 0 to 72. Higher values indicate more severe or extensive disease.
| Arm | Type | Description |
|---|---|---|
| Intravenous EVO301 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| EVO301 | BIOLOGICAL | Intravenous EVO301 |
| Placebo | BIOLOGICAL | Placebo |
Inclusion Criteria: 1. Males or non-pregnant, non-lactating females, age 18 years or older 2. Chronic atopic dermatitis for at least 6 months 3. BSA of AD involvement of at least 10% 4. EASI score of at least 16. Exclusion Criteria: 1. Significant AD flare with 4 weeks 2. Use of biologic therapy ...